

1 Immune modulatory effects of probiotic *Streptococcus thermophilus* on human  
2 monocytes

3

4 Narges Dargahi<sup>a,\*</sup>, Joshua Johnson<sup>b</sup>, Vasso Apostolopoulos<sup>a\*</sup>,

5

6

7

8 <sup>a</sup> *Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.*

9 <sup>b</sup> *Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne*

10 *VIC, Australia*

11

12

13

14 \* Corresponding authors at: Institute for Health and Sport, Victoria University, Hoppers

15 Lane, Werribee, VIC, PO Box 14428, Melbourne, Victoria 8001, Australia.

16

17 *Email addresses:*

18 Narges.Dargahi@live.vu.edu.au (N. Dargahi), Joshua.Johnson@vu.edu.au (J. Johnson),

19 Vasso.Apostolopoulos@vu.edu.au (V. Apostolopoulos)

20 Tel: + 61 3 9919 8109

21 Tel: +61 3 9919 2025

22

23

24

25 **ABSTRACT**

26 Ingesting probiotics contributes to the development of a healthy microflora in the  
27 gastrointestinal tract with established benefits to human health. Some of these beneficial  
28 effects may be through modulating of the immune system and probiotics have become more  
29 common in the treatment of many inflammatory and immune disorders. We demonstrate a  
30 range of immune modulating effects of *Streptococcus thermophilus* by human monocytes,  
31 including, decreased mRNA expression of IL-1R, IL-18, IFN $\gamma$ R1, IFN $\alpha$ R1, CCL2, CCR5,  
32 TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, TLR-8, CD14, CD86, CD4, ITGAM, LYZ, TYK2,  
33 IFNR1, IRAK-1, NOD2, MYD88, ITGAM, SLC11A1, and, increased expression of IL-1 $\alpha$ ,  
34 IL-1 $\beta$ , IL-2, IL-6, IL-8, IL-23, IFN $\gamma$ , TNF $\alpha$ , CSF-2. Routine administration of *Streptococcus*  
35 *thermophilus* in fermented dairy products, and their consumption may be beneficial to the  
36 treatment/management of inflammatory and autoimmune diseases.

37

38

39

40

41

42

43 *Keywords:*

44 Probiotics; microbiome; Lactic acid bacteria; *Streptococcus thermophilus*; Peripheral blood

45 mononuclear cells; Monocyte; RNA; Innate immune response; Adaptive immune response;

46 Inflammation

47

## 48 **1. Introduction**

49

50 The human body and, in particular, the gastrointestinal tract (GIT) hosts a variety of  
51 microbial populations collectively referred to as the microbiome [1]. The GIT microbiome  
52 plays a fundamental role in the maintenance of a healthy immune system [1, 2], and any  
53 disruption to the microbiome can lead to serious ill health effects [3, 4]. In order to maintain a  
54 healthy microbiome, regular ingestion of probiotic supplements either as capsules or in  
55 fermented dairy products has been suggested. These practices have led to various improved  
56 health outcomes and treatment of ill health, such as infections, constipation and diarrhoea [1,  
57 5, 6].

58

59 The majority of probiotics belong to the lactic acid bacteria (LAB) family; gram positive  
60 lactic acid producing microorganisms that include several genera such as bifidobacteria,  
61 lactobacilli streptococci and enterococci [1]. The small and large intestines are highly  
62 populated with these microorganisms [7-9], and are routinely supplemented in foods as live  
63 strains due to their established beneficial effects to human health [1, 2, 9-14]. *Streptococcus*  
64 species such as exopolysaccharide-producing strains of *Streptococcus thermophilus* (ST) [13,  
65 15, 16] are amongst those consumed. ST is used for fermentation of milk products and is  
66 recognized as an important species for its health benefits [17, 18]. In fact, ST and *L. brevis*  
67 synergistically display health benefits which are well established, also, ST is one of the  
68 bacteria in the VSL#3 probiotic mixture, which has been applied for the treatment of  
69 inflammatory conditions [19, 20]. Probiotics also interact with the immune system where  
70 they exhibit immunomodulatory and anti-inflammatory effects [3, 21, 22].

71

72 Use of probiotic bacteria can increase the abundance of and concurrently modulate immune  
73 cells including B, T helper (Th)-1, Th-2, Th-17 and regulatory T (Treg) cells. This in turn,  
74 directly influences human health and modulates pathologies of immune/autoimmune diseases  
75 [1, 2, 14]. In fact, primary macrophages co-cultured with ST bacteria have been shown to  
76 increase production of anti-inflammatory IL-10 and pro-inflammatory IL-12 cytokines [23].  
77 ST1275 and *Bifidobacterium longum* BL536 induce expression of high levels of transforming  
78 growth factor (TGF)-beta, a key factor in the differentiation of Treg and Th-17 cells by bulk  
79 peripheral blood mononuclear cell (PBMC) cultures [24]. Probiotic bacteria, however, can  
80 only confer these benefits through interaction with specific immune cells, primarily antigen  
81 presenting cells (APC), which include monocytes, as mediators between bacteria/foreign  
82 agents and the immune system's effector adaptive immune cells [25].

83

84 In line with these findings, we previously noted that ST1342, ST1275 and ST285 modulated  
85 U937 monocyte cell line by increasing IL-4, IL-10, GM-CSF and CXCL8 production. In  
86 addition the cell surface marker expression of CD11c, CD86, C206, CD209, MHC-1 were  
87 upregulated, suggesting that ST bacteria has an influence on the immune system [1].  
88 Furthermore, we recently showed that ST285 exerted an array of anti-inflammatory immune-  
89 modulatory properties to human PBMC [26]. In particular, ST285 decreased mRNA  
90 expression of IL-18, IFN $\gamma$ R1, CCR5, CXCL10, TLR-1, TLR-2, TLR-4, TLR-8, CD14,  
91 CD40, CD86, C3, GATA3, ITGAM, IRF7, NLP3, LYZ, TYK2, IFNR1, and upregulated IL-  
92 1 $\alpha$ , IL-1 $\beta$ , IL-6, IL-8, IL-10, IL-23, IFN $\gamma$ , TNF $\alpha$ , CSF-2 [26]. The data demonstrated a  
93 predominant anti-inflammatory profile exhibited by ST285. Due to the role of monocytes  
94 and their progeny in initiation and maintenance of both innate and adaptive immune  
95 responses, we now show immune modulatory properties of ST285 on monocytes from  
96 healthy blood donors. The data paves the way for further work to determine the effects of

97 ST285 in inflammatory disease models *in vitro* and *in vivo*, such as multiple sclerosis,  
98 inflammatory bowel disease and allergies.

## 99 **2. Material and methods**

100

### 101 **2.1. Bacterial strains**

102

103 Pure bacterial cultures of ST285 were obtained from Victoria University culture collection  
104 (Werribee, VIC, Australia). Stock cultures were stored in cryobeads at  $-80^{\circ}$  C. Prior to each  
105 experiment the cultures were propagated in M17 broth (Oxoid, Denmark) with 20 g/L lactose  
106 and incubated at  $37^{\circ}$  C under aerobic conditions. In order to confirm gram-positivity and  
107 assess purity, morphology and characteristics, bacteria were cultured in M17 agar (1.5 % w/v  
108 agar) with 20 g/L lactose (Oxoid, Denmark) as well [1].

109

### 110 **2.2 Preparation of live bacterial suspensions**

111

112 Prior to experiments bacteria medium was prepared and autoclaved at  $121^{\circ}$  C for 15 minutes  
113 (mins) and bacterial cultures were grown 3 times in M17 broth with 20 g/L lactose, at  $37^{\circ}$  C  
114 aerobically for 18 hours (hr) with a 1 % inoculum transfer rate [27] at  $37-42^{\circ}$  C [15].  
115 Bacteria were harvested during stationary growth phase on the day of experiment, centrifuged  
116 ( $6000\times g$ ) for 15 min at  $4^{\circ}$  C, followed by washing twice with phosphate-buffered saline  
117 (PBS) (Invitrogen, Pty Ltd. Australia) and resuspended in the Roswell Park Memorial  
118 Institute (RPMI) 1640 culture media (Invitrogen, Pty Ltd. Australia), which constituted the  
119 live-bacteria suspensions.

120

## 121 **2.4. Enumeration of bacterial cells**

122

123 Prior to co-culturing with PBMC, bacterial strains cultured in M17 broth, were centrifuged  
124 and transferred into PBS (Invitrogen, Pty Ltd. Australia), adjusted to a final concentration of  
125  $10^8$  colony forming units (cfu)/ml by measuring the optical density at 600 nm. Then washed  
126 twice with PBS and resuspended in RPMI 1640 (Invitrogen, Pty Ltd. Australia) [1].

127

## 128 **2.4. Isolation of monocytes from buffy coat**

129

130 Buffy coats were received from the Australian Red Cross blood bank in Melbourne, and  
131 PBMC were isolated using standard Ficoll-Paque density gradient centrifugation method as  
132 previously described [11]. PBMC cells were resuspended at  $\sim 5 \times 10^8$  cells/mL in adequate  
133 amount of Dulbecco's phosphate-buffered saline, D-PBS (D-PBS without  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$ )  
134 supplemented with 2% FBS and 3 mM cell culture grade EDTA (Life Technologies;  
135 ThermoFisher) prior to monocyte isolation. Monocytes were isolated using the EasySep  
136 Human Mono Isolation Kit (STEMCELL technology, Canada) [28]. Isolation method  
137 involved the use of immunomagnetic negative selection method targeting  $\text{CD16}^+$  monocytes,  
138 excluding non-monocyte cells, and platelets, yielding highly pure  $\text{CD14}^+\text{CD16}^-$  monocytes.  
139 As such the unwanted cell populations are labelled with specific cell surface marker  
140 antibodies and magnetic particles, and removed following separation by using an EasySep™  
141 magnet (STEMCELL technology, Canada) according to manufacturer's instructions [28].  
142 Monocyte cells were added into a fresh tube, checked for viability and purity.

143

## 144 **2.5. Stimulation of monocytes with ST285**

145

146 Monocytes ( $\sim 3\text{-}5 \times 10^7$  cells) isolated from three different donors were resuspended in RPMI  
147 1640 media supplemented with 10% heat-inactivated FBS (Invitrogen, Pty Ltd. Australia),  
148 1% antibiotic-antimycotic solution and 2 mM L-glutamine in cell culture flasks, into which  
149  $5 \times 10^8$  ST285 bacteria were added. Monocytes ( $\sim 3\text{-}5 \times 10^7$  cells) minus the ST285 bacteria  
150 were used as a control and incubated at  $37^\circ\text{C}$ , 5 %  $\text{CO}_2$  for 24 hrs [1]. In previous studies we  
151 demonstrated that 24 hrs co-culture was optimal for stimulation of the U937 monocyte cell  
152 line, and all incubations described herein were for 24 hrs [1]. Monocytes were harvested post  
153 incubation period, snap frozen and stored at  $-80^\circ\text{C}$ .

154

## 155 **2.6. RNA extraction from monocytes**

156

157 Total RNA was extracted from stimulated and unstimulated monocytes using the RNeasy®  
158 mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Briefly,  
159 monocytes were harvested using centrifugation, supernatants were removed and RNA was  
160 extracted from each pellet by resuspending pellet in lysis buffer supplemented with  $\beta$ -  
161 mercaptoethanol for cell disruption. Monocytes were lysed and each cell lysate was  
162 homogenized by passing through Qia-shredder columns (Qiagen, Hilden, Germany). Each  
163 monocytes lysate was then mixed 1:1 with 70% ethanol (equal volume) and were transferred  
164 onto RNeasy mini-spin columns. DNA was eliminated using DNase digestion/ treatment  
165 using RNase-Free DNase Set (Qiagen, Hilden, Germany) by adding it directly onto the  
166 columns. The RNA Integrity Number (RIN) of all RNA samples were determined using an  
167 Agilent 2100 Bioanalyzer and Agilent RNA 6000 nano kit (Agilent Technologies, Santa  
168 Clara, CA, USA). A minimum RIN of 7.5 was used as the standard for inclusion in the gene  
169 expression study. Subsequently, the concentration of each individual monocyte RNA sample  
170 was quantified using a Qubit RNA BR Assay (Invitrogen, Pty Ltd. Australia).

171

## 172 **2.7. Assessing changes in the expression of genes associated with innate and** 173 **adaptive immunity**

174

175 Using RT<sup>2</sup> first strand kit (Qiagen, Hilden, Germany), adequate aliquots of each RNA sample  
176 was reverse-transcribed to produce complementary DNA (cDNA) according to the  
177 manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR)  
178 was carried out by using the 'Human Innate and Adaptive immune Response' kit (Qiagen,  
179 Hilden, Germany) to assess the expression of genes/mRNA. Using a CFX Real-Time touch  
180 PCR System thermo-cycler (Biorad, Melbourne Australia) and Qiagen prescribed cycle, the  
181 relative gene/mRNA expression of ST285-treated monocytes were analyzed in contrast to  
182 control untreated monocytes. The RT<sup>2</sup> qPCR innate and adaptive immune response arrays  
183 targeted a set of 84 innate and adaptive immune-related genes, five housekeeping genes, an  
184 RT control, a positive PCR control, and a human genomic DNA contamination control [29].  
185 Relative gene expression was calculated using the Qiagen webportal PCR array data  
186 analysis web-based software (Qiagen, Germany). Differential expression (up and down  
187 regulation) of the genes were identified using the criteria of a > 2.0-fold increase/decrease  
188 in gene expressions in treated monocytes in comparison with those genes in control  
189 monocyte cultures.

190

## 191 **2.8. Data analysis**

192

193 The Delta-Delta CT ( $\Delta\Delta CT$ ) method was used for calculating fold-changes [30]. Fold-  
194 regulation represents fold-change results in a biologically meaningful way. In these RT2  
195 profiler PCR array results, fold-change values >1, indicate a positive (or an up-) regulation.



196 Actually, in the case of genes which are upregulated, the fold-regulation is equivalent to the  
197 fold-change. Fold-change rates  $<1$  indicate a negative (or a down) regulation. In the case of  
198 negative values, the fold-regulation is actually the negative inverse of the fold-change [31-  
199 33]. Data related to changes in the expression of the genes were estimated using Qiagen RT<sup>2</sup>  
200 profiler data analysis webportal that uses the  $\Delta\Delta CT$  method in calculating fold-changes. The  
201 raw CT values were uploaded to the Qiagen data analysis webportal with the lower limit of  
202 detection set for 35 cycles and 3 internal controls. For controls, RT efficiency, PCR array  
203 reproducibility, and genomic DNA contamination were assessed to ensure all arrays  
204 successfully passed all the control check-points. Normalization of the raw data was done by  
205 using the incorporated housekeeping genes (HKG) panel. Then using the  $\Delta\Delta CT$  method, both  
206 housekeeping gene references and controls (untreated monocytes in RPMI) were evaluated to  
207 determine relative expression of mRNA.

208

## 209 **2.9. Statistical analysis**

210

211 The p values were calculated by the use of a Student's *t-test* of the Triplicate  $2^{(-\Delta CT)}$   
212  $[(2^{-\Delta CT})]$  values for each gene in treatment groups (monocyte co-cultured with ST) and the  
213 control group (monocyte in RPMI media) [31, 32].

214

## 215 **3. Results**

216

217 Among 84 genes evaluated, expression of 30 genes were significantly altered with over 2.0  
218 fold up or down regulations in monocyte samples ( $n = 3$ ) following co-culture with ST285  
219 compared to control (Figure 1).

220

## 221 **3.1. ST285 alters cytokine gene expression levels of monocytes**

222

### 223 **3.1.1. ST285 causes upregulation of IL-1 $\alpha$ , IL-6 and IL-23 and** 224 **downregulation of IL-1R1 genes**

225

226 IL-1 $\alpha$  was upregulated  $4.66 \pm 0.7$  fold, IL-1 $\beta$  was upregulated  $9.83 \pm 0.49$  fold, IL-6 was  
227 upregulated  $42.23 \pm 0.32$  fold and IL-23 $\alpha$  was upregulated  $3.8 \pm 1.0$  fold (Figure 2). IL-1R1  
228 was downregulated  $2.11 \pm 0.36$  fold (Figure 2). Neither IL-17A nor IL-2, and IL-10 were  
229 altered following monocyte co-cultured with ST285.

230

### 231 **3.1.2. Modulation of pro-inflammatory cytokines**

232

233 ST285 induced upregulation of IFN $\gamma$  ( $29.33 \pm 0.26$  fold) (Figure 3A). IL-18 a Th1 inducing  
234 pro-inflammatory cytokine was downregulated ( $7.63 \pm 0.37$  fold) (Figure 3A). In addition,  
235 IFN $\gamma$ R1, a transmembrane protein which interacts with IFN $\gamma$ , was also downregulated  $5.65 \pm$   
236  $0.05$  fold and IFNAR1 (involved in defence against viruses) was downregulated  $2.53 \pm 0.05$   
237 fold (Figure 3A). Tumor-necrosis factor-alpha (TNF $\alpha$ ), which is important in the defense  
238 against bacterial infections, and in acute phase reactions was upregulated  $8.99 \pm 1.06$  fold  
239 (Figure 3). Gene expressions of other cytokines, IFNA1, IFNB1, IL-4, IL-5, IL-12 and IL-13  
240 were not significantly altered.

241

## 242 **3.2. ST285 alters chemokine gene expression levels of monocytes**

243

244 CCR5 a Th1 marker involved in immune response and CCL2 (MCP-1) involved in humoral  
245 immunity were down regulated  $11.54 \pm 0.23$  and  $24.33 \pm 1.44$  fold respectively (Figure 4).  
246 Chemokine (CXCL8, IL-8), important in the innate immune system, stimulates chemotaxis,  
247 was upregulated  $9.18 \pm 0.26$  fold following ST285 co-culture with monocyte cells (Figure 5).  
248 However, no significant differences were noted for gene expressions of other chemokines,  
249 including CXCL10 (INP10), CCL5 (RANTES), CCL8, CCR4, CCR8 and CXCR3 following  
250 monocytes' exposure to ST285.

251

### 252 **3.3. Significant upregulation of colony stimulating factor mRNA expression** 253 **levels**

254

255 Colony-stimulating factor (CSF)-2 which enables cell proliferation and differentiation of  
256 cells, was significantly increased by  $63.82 \pm 1.12$  fold (Figure 5) after co-culturing  
257 monocytes with ST285 bacteria.

258

### 259 **3.4. ST285 alters Toll like receptor gene expression levels of monocytes**

260

261 TLR (toll like receptor)-1, TLR-2, TLR-4, TLR-5, TLR-6 and TLR-8 are part of the innate  
262 immune response and involved in the defense response to bacteria. Monocytes co-cultured  
263 with ST285 induced significant differential downregulation of TLRs; TLR-1 ( $-3.63 \pm 0.14$ ),  
264 TLR-2 ( $-3.05 \pm 0.36$  fold), TLR-4 ( $-3.96 \pm 0.16$  fold), TLR-5 ( $-2.45 \pm 0.23$  fold), TLR-6 ( $-$   
265  $2.13 \pm 0.23$  fold), and TLR-8 ( $-2.51 \pm 0.12$  fold) (Figure 6). However, changes to TLR-3 and  
266 TLR-9 were not significant.

267

### 268 **3.5. Cell surface markers CD14, CD86 and CD4 mRNA expression levels**

269

270 Expression of the monocyte cell surface markers CD14 and CD86 were significantly  
271 downregulated  $34.08 \pm 3.42$  and  $10.16 \pm 0.14$  fold, respectively (Figure 7). CD4 is expressed  
272 by Th cells, monocytes, macrophages (MQ), and dendritic cells (DCs), was downregulated  
273  $7.14 \pm 0.41$  fold. No significant change was observed in the expression of CD8A, CD40,  
274 CD80, GATA3, FOXP3, STAT3, CD40LG (TNFSF5), HLA-A, HLA-E and RORC genes.

275

### 276 **3.6. Changes to other innate and adaptive molecules, mRNA expression** 277 **levels**

278

279 Altered expression levels are noted in other genes following ST285 co-culture with  
280 monocytes. Significant downregulation of the following genes were noted: TYK2 ( $-2.19 \pm$   
281  $0.37$ ), IRAK-1 ( $-2.27 \pm 0.45$ ), NOD2 ( $-2.35 \pm 0.04$ ), MYD88 ( $-2.98 \pm 0.23$ ), ITGAM ( $-3.6 \pm$   
282  $0.23$ ), MPO ( $3.71 \pm 0.12$ ), SLC11A1 ( $-4.7 \pm 0.17$ ) (Figure 8A), and LYZ ( $25.78 \pm 0.36$ )  
283 (Figure 8B). Other immune markers including FASLG (TNFSF6), ACTB, GATA3,  
284 complement component (C)-3, CRP, IFNAR1, JAK2, IL-1R1, MAPK8 (JNK1), IRF3,  
285 MBL2, NLRP3, NFKB1, MX1, ICAM1, MBL2, NOD1 (CARD4), DDX58 (RIG-I), RAG1,  
286 TICAM1 (TRIF) and IRF7 showed no significant mRNA gene changes in the levels of their  
287 expression.

288

## 289 **4. Discussion**

290

291 ST285 co-cultured with human monocytes resulted in significant changes to 30 genes  
292 associated with different immune responses of the innate and adaptive immunity compared to

293 control. In particular, mRNA gene expression of IL-1R, IL-18, IFN $\gamma$ R1, IFN $\alpha$ R1, CCL2,  
294 CCR5, TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, TLR-8, CD14, CD86, CD4, ITGAM, LYZ,  
295 TYK2, IFNR1, IRAK-1, NOD2, MYD88, ITGAM, SLC11A1 are downregulated. Whilst  
296 ST285 increases mRNA expression of IL-1 $\alpha$ , IL-1 $\beta$ , IL-1 $\alpha$ -R, IL-6, IL-8, IL-23, IFN $\gamma$ ,  
297 TNF $\alpha$  and CSF-2. These results were broadly in agreement with our previous findings  
298 showing a predominant anti-inflammatory profile by human PBMC upon co-culture with  
299 ST285 [26]. Likewise, our previous data showed a similar trend for a number of cytokine,  
300 chemokine and cell surface markers for three different ST bacteria to human U937 monocyte  
301 cell line, where ST285 was most effective [1].

302

303 **4.1. ST285 induces IL-1 $\alpha$  and IL-6 and downregulates IL-1R1.** IL-1 $\alpha$  secreted by DCs  
304 and MQs, usually initiates Th2 differentiation, while preventing polarization of Th1 cells  
305 [34]. IL-6 is produced by activated immune cells including monocytes/MQs [35]. IL-  
306 1 $\alpha$  and IL-6 are significantly upregulated, whereas IL-1R1 (CD121a), a key mediator  
307 associated with several inflammatory and immune responses is downregulated in monocytes  
308 after exposure to ST285. This is in accord to PBMCs co-cultured with ST285 [26] and U937  
309 monocyte cell line co-cultured with ST285 [1]. Likewise, it was recently noted that spleen  
310 cells from mice immunized with agonist myelin basic protein peptide (MBP<sub>83-99</sub>) peptide was  
311 cultured with ST285 in the presence of recall agonist peptide, which lead to significant  
312 production of IL-6 which was three times that of control without ST285 bacteria but with  
313 agonist peptide; these data suggested that ST285 has the potential to significantly change the  
314 balance towards a healthier state [36]. IL-6 acts as both pro- and anti-inflammatory cytokine  
315 [37] and its anti-inflammatory roles are associated with its inhibitory effects on IL-1, TNF- $\alpha$ ,  
316 and activation of IL-10 and IL-1Ra [37, 38]. On the other hand, the inhibitor of NF- $\kappa$ B kinase  
317 (IKK) governs IL-6 mRNA stability (through phosphorylation of regnase-1), in response to

318 IL-1R/TLR stimulation [39]. As such, *Lactobacillus paracasei* has been shown to reduce IL-  
319 6 production via prevention of NF- $\kappa$ B activation to THP-1 cell line [40] which is in contrast  
320 with our findings. Whereas, the surface-associated exopolysaccharide (EPS) extracted from  
321 *L. paracasei* DG showed immune-stimulating properties to human monocytic cell line THP-1  
322 by increasing TNF- $\alpha$  and IL-6 gene expression which is in line with our findings [41]. In  
323 addition, human monocytes and monocyte-derived DCs co-cultured with *Veillonella parvula*,  
324 *Escherichia (E.) coli*, *B. adolescentis* and *L. plantarum* strains, stimulated high level of IL-6  
325 upon exposure to *V. parvula* and *E. coli* but not *B. adolescentis* and *L. plantarum* [42].

326  
327 IL-1 $\beta$  is secreted by monocytes and activated MQs, is involved in regulating immune and  
328 inflammatory responses to bacterial infections and injuries, hence its role in innate immunity  
329 [43]. IL-1 $\beta$  is upregulated by ST285 co-cultured with monocytes, which is similar to ST285  
330 stimulation of PBMC [14], although ST285 did not stimulate IL-1 $\beta$  in the U937 monocyte  
331 cell line [1]. However, in other studies *L. paracasei* cultured with THP-1 cell line either  
332 before LPS treatment or together with LPS, reduced IL-1 $\beta$  secretion [40]. Additionally, mice  
333 immunized with agonist MBP<sub>83-99</sub> peptide, spleen cells cultured with recall agonist peptide in  
334 the presence of ST285 decreased production of IL-1 $\beta$  [36]. Consumption of a mixed probiotic  
335 or a conventional yogurt with equal *S. thermophiles*, *L. bulgaricus* and surplus *L. casei*  
336 DN114001, induces high IL-1 $\beta$  production by *ex vivo* cultured monocytes following LPS and  
337 phytohaemmagglutinin stimulation [44].

338  
339 The increased expression of IL-1 $\alpha$  and IL-6, suggests the role of ST285 in the induction of  
340 immune responses required for acute phase (including MQs differentiation, B cell maturation,  
341 and activation of Th2 differentiation and prevention of Th1 polarization). A decrease in IL-

342 1R1 gene expression could highlight the role of ST285 as a brake that controls the pro-  
343 inflammatory roles of both IL-6 and IL-1 $\alpha$ .

344

345 **4.2. ST285 changes expression of cytokines involved in inflammation and defence**

346 **against bacteria.** IL-18 is associated with severe inflammatory responses and plays a role in

347 inflammatory and autoimmune disorders. Monocytes co-cultured with ST285 significantly

348 reduced the gene expression of IL-18, which is in agreement with our recent study of ST285

349 co-cultured with PBMC [26], suggesting an anti-inflammatory role for ST285 bacteria. IFN- $\gamma$

350 is an important activator of MQs, is secreted by monocytes, NK and NKT cells, and is critical

351 for functional innate and adaptive immune responses against viruses, some bacterial and

352 protozoa infections [45]. Monocytes co-cultured with ST285 show increased gene expression

353 of IFN- $\gamma$  suggesting an anti-bacterial response. Similarly, blood monocytes from healthy

354 individuals who ingested either a probiotic mixed of *S. thermophiles*, *L. bulgaricus* and

355 surplus *L. casei* DN114001 or a conventional yogurt containing same probiotic mixture,

356 showed increased production of IFN- $\gamma$  upon co-culturing monocyte cells *ex vivo* with LPS

357 and phytohaemmagglutinin [44]. In another study, the effects of *L. casei* Shirota on monocyte

358 was shown indirectly; as depletion of monocytes from PBMC co-cultured with *L. casei*

359 Shirota was associated with an absence of IFN- $\gamma$  and other cytokines demonstrating the

360 importance of monocytes against bacterial challenge [46]. Similarly, *L. plantarum* alone and

361 mixed *L. plantarum* and *Helicobacter pylori* added to monocytes (and lymphocytes) resulted

362 in the production of high levels of IFN- $\gamma$  with *L. plantarum* alone, compared to the mixed

363 cultures [47]. In comparison, it was shown that IFN- $\gamma$  secretion was reduced by spleen cells

364 of mice immunized with agonist MBP<sub>83-99</sub> peptide in the presence of ST285. The reduction of

365 inflammatory IFN- $\gamma$  is important in the inflamed environment situations such as

366 inflammatory and inflammatory diseases because any level of reduction in the amount of  
367 inflammatory mediators can contribute to the relief of symptoms [36].

368

369 TNF $\alpha$ , a pro-inflammatory cytokine is required against bacterial infections and is involved in  
370 activating and recruiting T and B cells in the initiation of adaptive immune responses. We  
371 show upregulation of TNF $\alpha$  when human monocytes are co-cultured with ST285, in  
372 agreement with observations with PBMCs [26] and the U937 monocyte cell line [1]. Isolated  
373 human monocytes and monocyte-derived DCs co-cultured with *V. parvula*, *E. coli*, *B.*  
374 *adolescentis* and *L. plantarum* strains, similarly showed higher levels of TNF $\alpha$  [42]. In  
375 addition, EPS from *L. paracasei* DG also induced increased TNF $\alpha$  gene expression by THP-1  
376 monocyte cell line [41]. Although, *L. paracasei* itself decreased TNF- $\alpha$  production by THP-1  
377 cell line via inhibition of NF- $\kappa$ B activation [40]. Similarly, *L. plantarum* genomic DNA  
378 reduced the production of TNF $\alpha$  in THP-1 monocyte cells [48]. Additionally, the importance  
379 of monocytes in phagocytosis was shown by using monocyte-depleted-PBMC in co-culture  
380 with *L. casei* Shirota, which led to no secretion of TNF $\alpha$  [46]. Similarly, spleen cells from  
381 immunized with MBP<sub>83-99</sub> peptide mice demonstrated marginally decreased TNF $\alpha$  production  
382 in the presence of ST285 and recall MBP<sub>83-99</sub> peptide; marginal reduction of both TNF $\alpha$  and  
383 IFN- $\gamma$  subtractions could be advantageous for twisting inflamed status of diseases into  
384 healthier normal status [36].

385

386 IFNAR1 is a membrane protein and a receptor for both IFN $\alpha$  and IFN $\beta$  associated with  
387 defence against viruses. IFNAR1 signalling is involved in production of pro-inflammatory  
388 cytokines [49], as such that IFNAR1 knockout mice demonstrate reduced pro-inflammatory  
389 chemokines and cytokines [49]. IFNAR1 is significantly downregulated by monocytes  
390 following co-culture with ST285 supporting an anti-inflammatory role for ST285.



391 Upregulation of IFN $\gamma$ , IL-1 $\beta$  and TNF $\alpha$  by monocytes following ST285 co-culture suggests a  
392 powerful defense against invading pathogens induced by ST285 that could be advantageous  
393 in defense against virus infection and tumours. Of interest, in spite of the upregulation of  
394 IFN $\gamma$ , IL-1 $\beta$  and TNF $\alpha$ , considering collective down regulation of IFNAR1, IFNGR1, IL-18,  
395 our results might reveal an antagonistic effect of ST285 on pro-inflammatory IFN $\gamma$ , IL-1 $\beta$   
396 and TNF $\alpha$  responses which may lead to an overall downstream tolerance, and even an  
397 ultimate anti-inflammatory outcome.

398

#### 399 **4.3. ST285 activates mRNA expression of CXCL8 and downregulates CCR5 and CCL2.**

400 IL-8, also known as CXCL8 is produced by MQs; an important innate immune system  
401 chemokine which is associated with recruiting neutrophils and other granulocytes of innate  
402 immune defense [50]. Our findings show a significant increased IL-8 gene expression by  
403 monocytes after exposure to ST285. We previously noted that ST1342, ST1275 and ST285  
404 stimulate the U937 monocyte cell line to secrete increased levels of IL-8 [1]. Similarly, we  
405 showed PBMC exposure to ST285 results in overexpression of IL-8 [26]. Correspondingly,  
406 EPS from *L. paracasei* DG probiotic displayed immune-stimulating effects to human  
407 monocytic cell line THP-1 by increased expression of IL-8 gene [41]. In contrast, it was  
408 shown that dairy and soy fermented milks inoculated with *S. thermophilus* ST5 (ST5) mixed  
409 with either *L. helveticus* R0052 (R0052) or *B. longum* R0175 (R0175) added to LPS-  
410 challenged THP-1 monocyte cell line, decreased IL-8 production only when co-cultured with  
411 ST5+R0175 [51]. In addition, milk fermented with ST5+R0052 or ST5+R0175 did not alter  
412 the production of IL-8 by U937 monocyte cell line, whilst soy ferment prepared with  
413 ST5+R0175 downregulated IL-8 production [51].

414

415 C-C chemokine receptor type 5 (CCR5, CD195) and chemokine (C-C motif) ligand (CCL) 2  
416 are mainly expressed on monocytes, DCs and MQs [52]. CCR5 is associated with Th1  
417 immune responses and CCL2 with pathogenicity of a number of inflammatory diseases  
418 including rheumatoid arthritis and psoriasis, categorized by monocytic infiltrates through  
419 chemo-attracting monocytes [53]. Monocytes co-cultured with ST285 significantly  
420 downregulated CCR5 and CCL2, which is similar to ST285 co-cultured with PBMCs [26],  
421 suggesting an anti-inflammatory influence of ST285.

422

423 Although overexpression of IL-8 exclusively, may be interpreted as an inflammatory effect,  
424 taking into account the largely upregulated anti-inflammatory cocktail of cytokines and  
425 mediators induced by ST285, can in fact modulate this effect towards an anti-inflammatory  
426 profile for ST285. Upregulated IL-8 might be an initiating function of ST285 in order to  
427 trigger immune responses in the innate immune system, which then gets controlled by ST285  
428 through reduction in the expression of CCR5. This in turn may lead to reduced Th1 immune  
429 responses, as well as decreased CCL2 and subsequently resulting in a controlled recruitment  
430 of monocyte. These effects may again highlight immunomodulatory effects of ST285  
431 bacteria.

432

433 **4.4. ST285 significantly upregulates mRNA expression level of colony stimulating**  
434 **factor.** Colony stimulating factor (CSF, GM-CSF) is secreted by monocyte/MQs and  
435 supports and induces propagation, differentiation and production of different immune cells,  
436 mainly monocyte/MQs which are fundamental in responses against infections. CSF is  
437 significantly increased (63.82 fold) by monocyte cultures in the presence of ST285, which is  
438 in alignment to our recent data showing increased CSF gene expression by PBMC co-  
439 cultured with ST285 [26]. The secretion of GM-CSF showed insignificant difference amongst

440 immunized mouse spleen cells co-cultured with ST285 plus recall MBP<sub>83-99</sub> peptide analog,  
441 compared to culturing cells with media alone or media plus recall MBP<sub>83-99</sub> peptide analog  
442 [36]. In addition, ST1275, ST1342 and ST285 were also noted to induce high levels of GM-  
443 CSF production by U937 monocyte cell line [1]. It is known that G-CSF induces the  
444 development of IL-10-producing cells [54], hence, suggesting that ST285 may have an anti-  
445 inflammatory effect on the immune system.

446

447 **4.5. ST285 downregulates mRNA expression levels of toll-like receptors.** Toll-like  
448 receptors (TLRs) are mediators of innate immune responses primarily required in the defense  
449 against pathogens [55]. ST285 induced significant downregulation of TLR-1, TLR-2, TLR-4,  
450 TLR-5, TLR-6 and TLR-8, similar to our previous findings showing reduction of several  
451 TLRs by PBMC co-cultured with ST285[26]. Activated TLR (especially TLR-2 and TLR-4)  
452 together with other immune system factors can facilitate pro-inflammatory responses as well  
453 as further stimulating innate immune system actions [56-58]. Thus, an increased expression  
454 of TLR-2 and TLR-4 can lead to predominant inflammatory responses in the host, and their  
455 downregulation suggests reduction in such pro-inflammatory responses. Moreover, TLR-5  
456 activation leads to stimulation of NF- $\kappa$ B which results in pro-inflammatory TNF- $\alpha$   
457 production [59] and its reduced expression in monocyte co-cultured with ST285 may  
458 additionally signify an anti-inflammatory role for ST bacteria. Similar to our findings,  
459 another study has shown decreased expression of TLR-2, TLR-4, and TLR-9 using *L.*  
460 *plantarum* genomic DNA with THP-1 monocyte cells [48]. However, a study using human  
461 monocytes and monocyte-derived DCs exposed to UV-radiated *V. parvula*, *E. coli*, *B.*  
462 *adolescentis* and *L. plantarum*, showed higher expression of TLR-2 on monocytes compared  
463 to DCs, while TLR-4 was not detectable on DCs [42]. Additionally, in the same study it was  
464 shown that TLR-4 expression on monocytes was also down regulated in response to exposure

465 to either *E. coli* or *L. plantarum* [42]. Downregulation in mRNA expression of TLRs genes,  
466 specifically when it occurs across a wide range including TLR-1, TLR-2, TLR-4, TLR-5,  
467 TLR-6 and TLR-8, designates anti-inflammatory properties for ST285.

468

469 **4.6. ST285 downregulates cell surface markers CD14, CD86, CD4.** CD14 is expressed on  
470 the cell surface of monocytes, MQs and DC and primarily binds to bacterial components [60-  
471 62], CD14 was significantly downregulated when co-cultured with ST285 bacteria suggesting  
472 an anti-inflammatory response. CD14 together with TLR-4 bind to bacterial components and  
473 both CD14 and TLR-4 were downregulated in the presence of ST285 bacteria. Co-culture of  
474 PBMC with ST285 also led to downregulated CD14 and TLR-4 expression [26]. However,  
475 ST285 upregulated expression of CD14 by U937 monocyte cell line [1]. In accord to our  
476 findings, human monocytes isolated from PBMC and exposed to *E. coli* or *L. plantarum*  
477 displayed down-regulated expression of CD14 [42]. CD86 (B7-2), is a co-stimulatory  
478 molecule necessary for initiating and maintaining T cells. Expression of CD86 mRNA levels  
479 by monocyte is significantly downregulated following culture with ST285, in line with our  
480 previous findings where CD86 was downregulated by bulk PBMC cultures [26]. Therefore,  
481 ST285 seem to induce an anti-inflammatory profile. Likewise, ST5+R0052 or ST5+R0175  
482 milk or soy ferments also reduced expression of CD86 [51]. However, *L. fermentum* GR1485  
483 and *L. plantarum* WCFS1 increased expression of CD86 by monocytes, inversely to *L.*  
484 *delbruekii* and *L. rhamnosus* that reduced CD86 expression [63]. Additionally, monocyte  
485 derived immature DCs co-cultured with *L. lactis* subsp. *cremoris* ARH74, *B. breve* Bb99 and  
486 *S. thermophilus* THS increased the expression of CD86 [23]. The contrast in these findings is  
487 not surprising and may be due to the dissimilarities in the nature of experiments; co-culture of  
488 monocytes with ST285 bacteria only compared to differentiated monocytes into immature

489 DCs co-cultured with several probiotics or associated with differences in the properties of  
490 each bacteria.

491

492 CD4 is an extracellular cell surface molecule expressed by monocytes, MQ, DCs and Th cells  
493 and acts as a co-receptor between T cells and antigen presenting cells [64]. CD4 was  
494 significantly downregulated in monocyte cultures with ST285. In HIV-infected monocytes  
495 and MQs, CD4 is required for entry into the cell, and suggest that ST285 may have anti-viral  
496 properties.

497

498 Given the functional role of cell surface markers in immune responses, CD14 involvement in  
499 native immune responses, CD86 in T cell activation, and presence of CD4 on many cells  
500 underpinning innate and adaptive immunity, their downregulation in the presence of ST285  
501 indicates an anti-inflammatory and anti-stimulatory profile for ST285. Additionally, due to  
502 the role of these cell surface markers in mediating innate and/or adaptive immune responses  
503 in defence against bacteria, downregulation of such markers could be suggestive of ST285  
504 initiating self-tolerance via its immune modulation effects.

505

506 **4.7. ST285 differentially downregulates mRNA expression level of other innate and**  
507 **adaptive immune response markers and chemokines.** Integrin alpha M (ITGAM) or  
508 CD11b is another innate immune response factor associated with several inflammatory  
509 reactions such as phagocytosis, cell-mediated cytotoxicity, and chemotaxis. Lysozyme (LYZ)  
510 is also an innate immune response mediator associated with several inflammatory actions  
511 exists in mononuclear phagocytes such as MQs and performs as an antimicrobial enzyme.  
512 ITGAM and LYZ gene expressions are vastly downregulated in monocytes co-cultured with  
513 ST285, similarly to our recent findings showing downregulation of ITGAM and LYZ by

514 PBMC co-cultured with ST285 [26]. Conversely, in U937 monocyte cell line, exposure to  
515 ST285 caused significant upregulation of CD11b/ ITGAM [1], the contrast could be related  
516 to difference between monocytes from healthy blood donors compared to monocyte cell line.  
517 MYD88, implicated in innate immunity, is downregulated by monocytes in response to  
518 ST285 co-culture. IL1RA1 has been shown to interact with MYD88 (together with PIK3R1  
519 and IL1RAP) [65], is also downregulated, which both additionally highlight an anti-  
520 inflammatory role for ST285. Non-receptor tyrosine-protein kinase (TYK2) is an enzyme  
521 involved in various cellular events and extensive studies of TYK2-deficient mice indicate  
522 compromised IFN $\alpha$ , IL-12, and IL-23 pathways [66], and IL-12/Th1 and IL-23/Th17 axes  
523 [67], but it is dispensable for the signaling pathways of IL-6 or IL-10 [66]. It is believed that  
524 TKY2 is associated with a broader cellular pathways in human and it has a role in IL-12/Th1  
525 and IL-23/Th17 axes involved in inflammatory/ autoimmunity, highlighting TKY2 choice as  
526 an effective therapeutic approach for select autoimmune diseases [66]. TYK2 is significantly  
527 downregulated by monocytes upon co-culture with ST285, a similar trend was found in our  
528 results when PBMC co-cultured with ST285 recently [26], which mutually support an anti-  
529 inflammatory profile for ST285.

530

531 IL-1-receptor-associated kinase-1 (IRAK1) is involved in innate immunity, and ST285  
532 induced a significant downregulation of IRAK1 by monocyte culture. Likewise, *L. paracasei*  
533 stimulated the expression of IRAK3, but not IRAK1 in THP-1 cell line post differentiation  
534 with PMA. IRAK4 inhibitor suppressed the expression of negative regulators [40]. In  
535 contrast, THP-1 monocyte cells treated with *L. plantarum* genomic DNA induced a slight  
536 increase in IRAK-1 production [48]. SLC11A1 is a monocyte-MQ protein-1 involved in T  
537 cell activation and inflammatory disorders such as type 1 diabetes [68, 69], Crohn's disease  
538 [70] and rheumatoid arthritis [71], is downregulated by monocytes upon co-culture with

539 ST285. Our previous findings using ST285 to co-culture with PBMC similarly showed a  
540 reduced expression of SLC11A1[26], again suggesting an anti-inflammatory role for ST285.  
541 Induced downregulation of IRAK1, MYD88, TYK2, ITGAM, NOD2, SLC11A1 and LYZ by  
542 monocytes due to exposure to ST285 is suggestive of anti-inflammatory effects of ST285.

543

## 544 **5. Conclusion**

545

546 Commensal bacteria and probiotics have made their entry to the mainstream of healthcare and  
547 contribute to immune homeostasis in the gastrointestinal tract as well as conferring beneficial  
548 immunomodulatory properties that assist in the maintenance of a healthy immune system. ST  
549 is commonly applied in dairy products to ferment cheeses and yogurts and is thought to be  
550 beneficial to human health. We assessed the immune modulatory effects of ST285 on human  
551 monocytes and demonstrated that it delivers a range of potential immunomodulatory and anti-  
552 inflammatory properties. ST285 decreases mRNA expression of IL-1R, IL-18, IFN $\gamma$ R1,  
553 IFN $\alpha$ R1, CCL2, CCR5, TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, TLR-8, CD14, CD86, CD4,  
554 ITGAM, LYZ, TYK2, IFNR1, IRAK-1, NOD2, MYD88, ITGAM, SLC11A1, and  
555 upregulates IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-6, IL-8, IL-23, IFN $\gamma$ , TNF $\alpha$ , CSF-2. No changes to  
556 mRNA expression were noted with IL-4, IL-5, IL-13, CCL2, CCL5, CCL8, CCR4, CCR8,  
557 CXCR3, CXCL10, TLR-3, TLR-9, CD8A, CD40, CD80, IFNB1, MPO, FOXP3, GATA3,  
558 STAT3, CD40LG, HLA-A, HLA-E, RORC. The data exhibits a predominant anti-  
559 inflammatory profile of cytokine, chemokine and cell markers induced by ST285. Therefore,  
560 the use of ST285 may be an efficacious approach for the treatment of select autoimmune  
561 diseases without using broad immunosuppression caused by currently available treatments for  
562 autoimmune disorders. Supplementary work is required to determine whether ST bacteria

563 displays similar anti-inflammatory effects *in vitro* and *in vivo* in compromised immune  
564 disorders/ models such as inflammatory bowel disease, multiple sclerosis and allergies.

565

## 566 **Acknowledgements**

567 All authors were supported by the Institute for Health and Sport and the Institute for  
568 Sustainable Industries and Liveable Cities at Victoria University. JJ was supported by a VU  
569 Research Fellowship, Victoria University Australia.

570

## 571 **Conflict of interest**

572 The authors declare no conflicts of interest.

573

## 574 **References**

575

- 576 1. Dargahi, N., et al., *Immunomodulatory effects of Streptococcus thermophilus on U937*  
577 *monocyte cell cultures*. Journal of Functional Foods, 2018. **49**: p. 241-249.
- 578 2. Dargahi, N., et al., *Multiple sclerosis: Immunopathology and treatment update*. Brain  
579 Sciences, 2017. **7**(7).
- 580 3. Stagg, J., et al., *CD73-deficient mice have increased antitumor immunity and are resistant to*  
581 *experimental metastasis*. Cancer Research, 2011. **71**(8): p. 2892-2900.
- 582 4. Stagg, A.J., et al., *Interactions between dendritic cells and bacteria in the regulation of*  
583 *intestinal immunity*. Best Practice and Research: Clinical Gastroenterology, 2004. **18**(2): p.  
584 255-270.
- 585 5. Hardy, H., et al., *Probiotics, prebiotics and immunomodulation of gut mucosal defences:*  
586 *Homeostasis and immunopathology*. Nutrients, 2013. **5**(6): p. 1869-1912.
- 587 6. Kinross, J.M., et al., *The human gut microbiome: Implications for future health care*. Current  
588 Gastroenterology Reports, 2008. **10**(4): p. 396-403.
- 589 7. Michałkiewicz, J., et al., *Immunomodulatory Effects of Lactic Acid Bacteria on Human*  
590 *Peripheral Blood Mononuclear Cells*. Microbial Ecology in Health and Disease, 2003. **15**(4): p.  
591 185-192.
- 592 8. Maassen, C.B.M., et al., *Strain-dependent induction of cytokine profiles in the gut by orally*  
593 *administered Lactobacillus strains*. Vaccine, 2000. **18**(23): p. 2613-2623.
- 594 9. Fink, L.N., et al., *Distinct gut-derived lactic acid bacteria elicit divergent dendritic cell-*  
595 *mediated NK cell responses*. International Immunology, 2007. **19**(12): p. 1319-1327.
- 596 10. Asarat, M., et al., *Short-chain fatty acids regulate cytokines and Th17/treg cells in human*  
597 *peripheral blood mononuclear cells in vitro*. Immunological Investigations, 2016. **45**(3): p.  
598 205-222.
- 599 11. Asarat, M., et al., *Short-chain fatty acids produced by synbiotic mixtures in skim milk*  
600 *differentially regulate proliferation and cytokine production in peripheral blood mononuclear*  
601 *cells*. International Journal of Food Sciences and Nutrition, 2015. **66**(7): p. 755-765.



- 602 12. Asarat, M., et al., *Short-Chain Fatty Acids Regulate Secretion of IL-8 from Human Intestinal*  
603 *Epithelial Cell Lines in vitro*. Immunological Investigations, 2015. **44**(7): p. 678-693.
- 604 13. Salazar, N., et al., *Production of exopolysaccharides by Lactobacillus and Bifidobacterium*  
605 *strains of human origin, and metabolic activity of the producing bacteria in milk*. Journal of  
606 Dairy Science, 2009. **92**(9): p. 4158-4168.
- 607 14. Dargahi, N., et al., *Immunomodulatory effects of probiotics: Can they be used to treat*  
608 *allergies and autoimmune diseases?* Maturitas, 2019. **119**: p. 25-38.
- 609 15. Purwandari, U. and T. Vasiljevic, *Rheological properties of fermented milk produced by a*  
610 *single exopolysaccharide producing Streptococcus thermophilus strain in the presence of*  
611 *added calcium and sucrose*. International Journal of Dairy Technology, 2009. **62**(3): p. 411-  
612 421.
- 613 16. Di Caro, S., et al., *Effects of Lactobacillus GG on genes expression pattern in small bowel*  
614 *mucosa*. Digestive and Liver Disease, 2005. **37**(5): p. 320-329.
- 615 17. Hols, P., et al., *New insights in the molecular biology and physiology of Streptococcus*  
616 *thermophilus revealed by comparative genomics*. FEMS Microbiology Reviews, 2005. **29**(3  
617 SPEC. ISS.): p. 435-463.
- 618 18. Uriot, O., et al., *Streptococcus thermophilus: From yogurt starter to a new promising*  
619 *probiotic candidate?* Journal of Functional Foods, 2017. **37**: p. 74-89.
- 620 19. Mennigen, R., et al., *Probiotic mixture VSL#3 protects the epithelial barrier by maintaining*  
621 *tight junction protein expression and preventing apoptosis in a murine model of colitis*.  
622 American Journal of Physiology - Gastrointestinal and Liver Physiology, 2009. **296**(5): p.  
623 G1140-G1149.
- 624 20. Dai, C., et al., *VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF- $\kappa$ B*  
625 *pathway in rat model of DSS-induced colitis*. Molecular and Cellular Biochemistry, 2013.  
626 **374**(1-2): p. 1-11.
- 627 21. Han, G.K., et al., *Lipoteichoic acid isolated from Lactobacillus plantarum inhibits*  
628 *lipopolysaccharide-induced TNF- $\alpha$  production in THP-1 cells and endotoxin shock in mice*.  
629 Journal of Immunology, 2008. **180**(4): p. 2553-2561.
- 630 22. Vliagoftis, H., et al., *Probiotics for the treatment of allergic rhinitis and asthma: systematic*  
631 *review of randomized controlled trials*. Annals of Allergy, Asthma & Immunology, 2008.  
632 **101**(6): p. 570-579.
- 633 23. Latvala, S., et al., *Potentially probiotic bacteria induce efficient maturation but differential*  
634 *cytokine production in human monocyte-derived dendritic cells*. World Journal of  
635 Gastroenterology, 2008. **14**(36): p. 5570-5583.
- 636 24. Donkor, O.N., et al., *Cytokine profile and induction of T helper type 17 and regulatory T cells*  
637 *by human peripheral mononuclear cells after microbial exposure*. Clinical and Experimental  
638 Immunology, 2012. **167**(2): p. 282-295.
- 639 25. Gaudino, S.J. and P. Kumar, *Cross-talk between antigen presenting cells and T cells impacts*  
640 *intestinal homeostasis, bacterial infections, and tumorigenesis*. Frontiers in Immunology,  
641 2019. **10**(MAR).
- 642 26. Dargahi, N., J. Johnson, and V. Apostolopoulos, *Streptococcus thermophilus alters the*  
643 *expression of genes associated with innate and adaptive immunity in human peripheral*  
644 *blood mononuclear cells*. PLoS ONE, 2020. **15**(2).
- 645 27. Husson-Kao, C., et al., *The Streptococcus thermophilus autolytic phenotype results from a*  
646 *leaky prophage*. Applied and Environmental Microbiology, 2000. **66**(2): p. 558-565.
- 647 28. Marzaioli, V., et al., *NOX5 and p22phox are 2 novel regulators of human monocytic*  
648 *differentiation into dendritic cells*. Blood, 2017. **130**(15): p. 1734-1745.
- 649 29. Kaur, R., J. Casey, and M. Pichichero, *Differences in innate immune response gene regulation*  
650 *in the middle ear of children who are otitis prone and in those not otitis prone*. American  
651 Journal of Rhinology and Allergy, 2016. **30**(6): p. e218-e223.

- 652 30. Livak, K.J. and T.D. Schmittgen, *Analysis of Relative Gene Expression Data Using Real-Time*  
653 *Quantitative PCR and the 2- $\Delta\Delta$ CT Method*. *Methods*, 2001. **25**(4): p. 402-408.
- 654 31. Zhang, T., et al., *Protective effect of aspirin-triggered resolvin D1 on hepatic*  
655 *ischemia/reperfusion injury in rats: The role of miR-146b*. *International*  
656 *Immunopharmacology*, 2017. **51**: p. 140-147.
- 657 32. Yang, Z., et al., *miR-203 protects microglia mediated brain injury by regulating inflammatory*  
658 *responses via feedback to MyD88 in ischemia*. *Molecular Immunology*, 2015. **65**(2): p. 293-  
659 301.
- 660 33. Souza, B.M., et al., *Lactococcus lactis carrying the pValac eukaryotic expression vector coding*  
661 *for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-*  
662 *producing regulatory cells*. *Microbial Cell Factories*, 2016. **15**(1).
- 663 34. Ben-Sasson, S.Z., et al., *IL-1 acts directly on CD4 T cells to enhance their antigen-driven*  
664 *expansion and differentiation*. *Proceedings of the National Academy of Sciences of the*  
665 *United States of America*, 2009. **106**(17): p. 7119-7124.
- 666 35. Choy, E. and S. Rose-John, *Interleukin-6 as a multifunctional regulator: Inflammation,*  
667 *immune response, and fibrosis*. *Journal of Scleroderma and Related Disorders*, 2017. **2**: p. S1-  
668 S5.
- 669 36. Dargahi, N., J. Matsoukas, and V. Apostolopoulos, *Streptococcus thermophilus ST285 alters*  
670 *pro-inflammatory to anti-inflammatory cytokine secretion against multiple sclerosis peptide*  
671 *in mice*. *Brain Sciences*, 2020. **10**(2).
- 672 37. Scheller, J., et al., *The pro- and anti-inflammatory properties of the cytokine interleukin-6*.  
673 *Biochimica et Biophysica Acta - Molecular Cell Research*, 2011. **1813**(5): p. 878-888.
- 674 38. Garbers, C., et al., *Plasticity and cross-talk of Interleukin 6-type cytokines*. *Cytokine and*  
675 *Growth Factor Reviews*, 2012. **23**(3): p. 85-97.
- 676 39. Iwasaki, H., et al., *The I $\kappa$ B kinase complex regulates the stability of cytokine-encoding mRNA*  
677 *induced by TLR-IL-1R by controlling degradation of regnase-1*. *Nature Immunology*, 2011.  
678 **12**(12): p. 1167-1175.
- 679 40. Sun, K.-Y., et al., *Lactobacillus paracasei modulates LPS-induced inflammatory cytokine*  
680 *release by monocyte-macrophages via the up-regulation of negative regulators of NF-*  
681 *kappaB signaling in a TLR2-dependent manner*. *Cytokine*, 2017. **92**: p. 1-11.
- 682 41. Balzaretto, S., et al., *A novel rhamnase-rich hetero-exopolysaccharide isolated from*  
683 *Lactobacillus paracasei DG activates THP-1 human monocytic cells*. *Applied and*  
684 *Environmental Microbiology*, 2017. **83**(3).
- 685 42. Karlsson, H., et al., *Pattern of Cytokine Responses to Gram-Positive and Gram-Negative*  
686 *Commensal Bacteria Is Profoundly Changed when Monocytes Differentiate into Dendritic*  
687 *Cells*. *Infection and Immunity*, 2004. **72**(5): p. 2671-2678.
- 688 43. Lopez-Castejon, G. and D. Brough, *Understanding the mechanism of IL-1beta secretion*.  
689 *Cytokine Growth Factor Rev*, 2011. **22**(4): p. 189-95.
- 690 44. Meyer, A.L., et al., *Probiotic, as well as conventional yogurt, can enhance the stimulated*  
691 *production of proinflammatory cytokines*. *Journal of Human Nutrition and Dietetics*, 2007.  
692 **20**(6): p. 590-598.
- 693 45. Schoenborn, J.R. and C.B. Wilson, *Regulation of Interferon- $\gamma$  During Innate and Adaptive*  
694 *Immune Responses*, in *Advances in Immunology*. 2007. p. 41-101.
- 695 46. Shida, K., et al., *Essential roles of monocytes in stimulating human peripheral blood*  
696 *mononuclear cells with Lactobacillus casei to produce cytokines and augment natural killer*  
697 *cell activity*. *Clinical and Vaccine Immunology*, 2006. **13**(9): p. 997-1003.
- 698 47. Wiese, M., et al., *Immunomodulatory effects of Lactobacillus plantarum and helicobacter*  
699 *pylori CagA+ on the expression of selected superficial molecules on monocyte and lymphocyte*  
700 *and the synthesis of cytokines in whole blood culture*. *Journal of Physiology and*  
701 *Pharmacology*, 2012. **63**(3): p. 217-224.

- 702 48. Hee Kim, C., et al., *Probiotic genomic DNA reduces the production of pro-inflammatory*  
703 *cytokine tumor necrosis factor-alpha*. FEMS Microbiology Letters, 2012. **328**(1): p. 13-19.
- 704 49. Goritzka, M., et al., *Alpha/beta interferon receptor signaling amplifies early proinflammatory*  
705 *cytokine production in the lung during respiratory syncytial virus infection*. Journal of  
706 Virology, 2014. **88**(11): p. 6128-6136.
- 707 50. Baggiolini, M. and I. Clark-Lewis, *Interleukin-8, a chemotactic and inflammatory cytokine*.  
708 FEBS Letters, 1992. **307**(1): p. 97-101.
- 709 51. Masotti, A.I., et al. *Effects of soy and dairy ferments on monocyte viability, cytokine*  
710 *production and cell surface molecule expression: Impact in a low-shear modeled microgravity*  
711 *system*. in *61st International Astronautical Congress 2010, IAC 2010*. 2010.
- 712 52. Deshmane, S.L., et al., *Monocyte chemoattractant protein-1 (MCP-1): An overview*. Journal  
713 of Interferon and Cytokine Research, 2009. **29**(6): p. 313-325.
- 714 53. Lee, I., et al., *Blocking the Monocyte Chemoattractant Protein-1/CCR2 Chemokine Pathway*  
715 *Induces Permanent Survival of Islet Allografts through a Programmed Death-1 Ligand-1-*  
716 *Dependent Mechanism*. Journal of Immunology, 2003. **171**(12): p. 6929-6935.
- 717 54. Malashchenko, V.V., et al., *Direct anti-inflammatory effects of granulocyte colony-*  
718 *stimulating factor (G-CSF) on activation and functional properties of human T cell*  
719 *subpopulations in vitro*. Cellular Immunology, 2018. **325**: p. 23-32.
- 720 55. Kawai, T. and S. Akira, *The role of pattern-recognition receptors in innate immunity: Update*  
721 *on toll-like receptors*. Nature Immunology, 2010. **11**(5): p. 373-384.
- 722 56. Sugitharini, V., et al., *TLR2 and TLR4 co-activation utilizes distinct signaling pathways for the*  
723 *production of Th1/Th2/Th17 cytokines in neonatal immune cells*. Cytokine, 2016. **85**: p. 191-  
724 200.
- 725 57. Islam, M.A., et al., *Alveolar macrophage phagocytic activity is enhanced with LPS priming,*  
726 *and combined stimulation of LPS and lipoteichoic acid synergistically induce pro-*  
727 *inflammatory cytokines in pigs*. Innate Immunity, 2013. **19**(6): p. 631-643.
- 728 58. Sugitharini, V., et al., *TLR-mediated inflammatory response to neonatal pathogens and co-*  
729 *infection in neonatal immune cells*. Cytokine, 2014. **69**(2): p. 211-217.
- 730 59. Galli, R., et al., *TLR stimulation of prostate tumor cells induces chemokine-mediated*  
731 *recruitment of specific immune cell types*. Journal of Immunology, 2010. **184**(12): p. 6658-  
732 6669.
- 733 60. Bron, P.A., et al., *Cell surface-associated compounds of probiotic lactobacilli sustain the*  
734 *strain-specificity dogma*. Current Opinion in Microbiology, 2013. **16**(3): p. 262-269.
- 735 61. van Baarlen, P., J.M. Wells, and M. Kleerebezem, *Regulation of intestinal homeostasis and*  
736 *immunity with probiotic lactobacilli*. Trends in Immunology, 2013. **34**(5): p. 208-215.
- 737 62. Lee, I.C., et al., *The quest for probiotic effector molecules - Unraveling strain specificity at the*  
738 *molecular level*. Pharmacological Research, 2013. **69**(1): p. 61-74.
- 739 63. Hajebi, A., et al., *Major anxiety disorders in Iran: Prevalence, sociodemographic correlates*  
740 *and service utilization*. BMC Psychiatry, 2018. **18**(1).
- 741 64. Glatzová, D. and M. Cebecauer, *Dual role of CD4 in peripheral T lymphocytes*. Frontiers in  
742 Immunology, 2019. **10**(APR).
- 743 65. Huang, J., et al., *Recruitment of IRAK to the interleukin 1 receptor complex requires*  
744 *interleukin 1 receptor accessory protein*. Proceedings of the National Academy of Sciences of  
745 the United States of America, 1997. **94**(24): p. 12829-12832.
- 746 66. Sohn, S.J., et al., *A restricted role for TYK2 catalytic activity in human cytokine responses*  
747 *revealed by novel TYK2-selective inhibitors*. Journal of Immunology, 2013. **191**(5): p. 2205-  
748 2216.
- 749 67. Ishizaki, M., et al., *Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17*  
750 *axes in vivo*. Journal of Immunology, 2011. **187**(1): p. 181-189.

- 751 68. Thayer, T.C., S.B. Wilson, and C.E. Mathews, *Use of nonobese diabetic mice to understand*  
752 *human type 1 diabetes*. Endocrinology and Metabolism Clinics of North America, 2010.  
753 **39**(3): p. 541-561.
- 754 69. Dai, Y.D., et al., *Slc11a1 enhances the autoimmune diabetogenic T-cell response by altering*  
755 *processing and presentation of pancreatic islet antigens*. Diabetes, 2009. **58**(1): p. 156-164.
- 756 70. Stewart, L.C., et al., *SLC11A1 polymorphisms in inflammatory bowel disease and*  
757 *Mycobacterium avium subspecies paratuberculosis status*. World Journal of  
758 Gastroenterology, 2010. **16**(45): p. 5727-5731.
- 759 71. Archer, N.S., N.T. Nassif, and B.A. O'Brien, *Genetic variants of SLC11A1 are associated with*  
760 *both autoimmune and infectious diseases: Systematic review and meta-analysis*. Genes and  
761 Immunity, 2015. **16**(4): p. 275-283.
- 762 72. Goad, J., et al., *Differential Wnt signaling activity limits epithelial gland development to the*  
763 *anti-mesometrial side of the mouse uterus*. Developmental Biology, 2017. **423**(2): p. 138-151.
- 764 73. Gaston, J.D., et al., *Gene Expression Changes in Long-Term in Vitro Human Blood-Brain*  
765 *Barrier Models and Their Dependence on a Transwell Scaffold Material*. Journal of Healthcare  
766 Engineering, 2017. **2017**.
- 767 74. Abubaker, J., et al., *DNAJB3/HSP-40 Cochaperone Is Downregulated in Obese Humans and Is*  
768 *Restored by Physical Exercise*. PLoS ONE, 2013. **8**(7).

769

## 770 **Figure Legends**

771

772 **Fig. 1.** Effects of co-culturing ST285 with monocytes (n=3) on gene/RNA expression  
773 compared to control monocytes after 24 hrs. (A) All 84 genes are shown including those with  
774 significant high up/down regulated genes (more than 2-fold) and those with no significant  
775 change (less than 2-fold). The housekeeping genes (HKG) panel and other genes used for  
776 normalization of the raw data are not presented. In case of no letter or comments, the  
777 expression of gene/s is relatively high in both the test and control group (threshold cycle (CT)  
778 is <30). Letter A specifies the gene's average threshold cycle to be reasonably high (> 30) in  
779 either the treated samples or the controls and relatively low (< 30) in the other/opposite  
780 sample. Thus, in case of presenting fold changes with letter A, the estimate fold change may  
781 be an underestimate. Letter B suggests a reasonably high (> 30) gene's average threshold  
782 cycle that means a low level of average expression of relevant gene, in both test/treated  
783 samples and untreated control samples, and the p-value for the fold-change might be either  
784 relatively high (p > 0.05). Thus, in case of presenting fold changes with letter B, the estimate  
785 fold change may be slightly overestimate or unavailable. Letter C indicates that that gene's

786 average threshold cycle is either not determined or greater than the defined default 35 cut-off  
787 value, in both test/treated samples and control samples, suggesting that its expression was not  
788 detectable, resulting in the fold-change values being un-interpretable [72-74] . (B)  
789 Presentation of data as a heatmap of average gene/RNA expressions of monocytes (n=3) co-  
790 cultured with ST285, compared to control. Green represents down regulated genes to red  
791 represents upregulated genes.

792

793 **Fig. 2.** (A) IL-1 $\alpha$ , IL-1 $\beta$ , IL-23 $\alpha$ , IL-1R1 and (B) IL-6, mRNA fold change following 24 h  
794 co-culture of ST285 with monocytes (n=3), compared to control monocytes. The innate and  
795 adaptive RT<sup>2</sup> gene profiler arrays were used to determine changes in gene expression.  
796 Symbols represent *p* value for Tukey Test (One way ANOVA) where \*\* *p* < 0.04 and \*\*\* *p*  
797 < 0.02.

798

799 **Fig. 3.** IL-18, IFN- $\gamma$ , and IFN- $\gamma$ -R1, IFN- $\alpha$ -R1 and TNF mRNA mRNA fold change  
800 following 24 h co-culture of ST285 with monocytes (n=3), compared to control monocytes.  
801 The innate and adaptive RT<sup>2</sup> gene profiler arrays were used to determine changes in gene  
802 expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \* *p* < 0.05  
803 and \*\*\* *p* < 0.02.

804

805 **Fig. 4.** CCR5, CXCL8 (IL-8) and CCL2 mRNA fold change following 24 h co-culture of  
806 ST285 with monocytes (n=3), compared to control monocytes. The innate and adaptive RT<sup>2</sup>  
807 gene profiler arrays were used to determine changes in gene expression. Symbol represents *p*  
808 value for Tukey Test (One way ANOVA) where \*\* *p* < 0.04.

809

810 **Fig. 5.** CSF-2, mRNA fold change following 24 h co-culture of ST285 with monocytes  
811 (n=3), compared to control monocytes. The innate and adaptive RT<sup>2</sup> gene profiler arrays were  
812 used to determine changes in gene expression. Symbol represents *p* value for Tukey Test  
813 (One way ANOVA) where \*\*\*\*  $p < 0.01$ .

814

815 **Fig. 6.** TLR-1, TLR-2, TLR-4, TLR-5, TLR-6 and TLR-8, mRNA fold change following 24  
816 h co-culture of ST285 with monocytes (n=3), compared to control monocytes. The innate and  
817 adaptive RT<sup>2</sup> gene profiler arrays were used to determine changes in gene expression.  
818 Symbol represents *p* value for Tukey Test (One way ANOVA) where \*  $p < 0.05$ .

819

820 **Fig. 7.** CD14, CD86 and CD4 mRNA fold change following 24 h co-culture of ST285 with  
821 monocytes (n=3), compared to control monocytes. The innate and adaptive RT<sup>2</sup> gene profiler  
822 arrays were used to determine changes in gene expression. Symbols represent *p* value for  
823 Tukey Test (One way ANOVA) where \*  $p < 0.05$  and \*\*\*  $p < 0.02$ .

824

825 **Fig. 8.** (A) TYK2, IRAK1, NOD2, MYD88, ITGAM, SLC11A1 and (B) LYZ and GATA3,  
826 mRNA fold change following 24 h co-culture of ST285 with monocytes (n=3), compared to  
827 control monocytes. The innate and adaptive RT<sup>2</sup> gene profiler arrays were used to determine  
828 changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA)  
829 where \*  $p < 0.05$ , \*\*  $p < 0.04$ , \*\*\*  $p < 0.02$  and \*\*\*\*  $p < 0.01$ .

**Figure 1.****A**

Layout	01	02	03	04	05	06	07	08	09	10	11	12
<b>A</b>	APCS 1.05 C	C3  -1.67	CASP1  1.37	CCL2  -24.33	CCL5  1.72	CCR4 1.08 B	CCR5  -11.54	CCR6 1.25 B	CCR8 -1.09 B	CD14  -34.08	CD4 -7.14 B	CD40  1.08
<b>B</b>	CD40LG -1.01 B	CD80  -1.79	CD86  -10.16	CD8A -3.14 B	CRP 1.05 C	CSF2 63.82 A	CXCL10  1.09	CXCR3 -1.45 B	DDX58  -1.74	FASLG -1.30 A	FOXP3 -2.21 A	GATA3 -1.23 B
<b>C</b>	HLA-A  -1.70	HLA-E  -1.35	ICAM1  -1.17	IFNA1 -1.59 B	IFNAR1  -2.53	IFNB1 -1.14 B	IFNG 29.33 A	IFNGR1  -5.65	IL10  -1.12	IL13 -1.05 B	IL17A 1.05 C	IL18 -7.63 A
<b>D</b>	IL1A  4.66	IL1B  9.83	IL1R1  -2.11	IL2 -1.35 B	IL23A  11.79	IL4 1.33 B	IL5 1.10 B	IL6  45.23	CXCL8  9.18	IRAK1  -2.27	IRF3  -1.23	IRF7  -1.14
<b>E</b>	ITGAM -3.60 A	JAK2  -1.57	LY96  -1.81	LYZ  -25.78	MAPK1  -1.68	MAPK8  -1.18	MBL2 1.05 C	MPO -3.71 B	MX1  -1.46	MYD88  -2.98	NFKB1  1.41	NFKBIA  -1.23
<b>F</b>	NLRP3  -1.38	NOD1 -1.51 A	NOD2  -2.35	RAG1 1.01 B	RORC -1.29 B	SLC11A1  -4.70	STAT1  1.23	STAT3  -1.35	STAT4  1.14	STAT6  -1.31	TBX21  1.79	TICAM1  1.12
<b>G</b>	TLR  -3.62	TLR2  -3.05	TLR3 -1.74 B	TLR4  -3.96	TLR5 -2.45 A	TLR6 -2.13 A	TLR7 -1.40 B	TLR8  -2.51	TLR9 -1.36 B	TNF  8.99	TRAF6  -1.42	TYK2  -2.19



**B****Magnitude of  $\log_2(\text{Fold Change})$** 

Figure 2.






Figure 3.




Figure 4.




Figure 5.




Figure 6.




Figure 7.




Figure 8.

